Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S010 - Hot Topics in Medical Dermatology

Saturday, July 27; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Select optimal therapies for patients with a number of cutaneous disorders including psoriasis and atopic dermatitis.
  • Identify the cutaneous manifestations of various travelers dermatoses
  • Diagnose and treat life-threatening dermatoses such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and immunobullous diseases more effectively

Description

Topics to be covered include new developments in the diagnosis and treatment of skin cancers; epidemiology and diagnosis of travelers dermatoses including viruses such as Zika, Chikungunya and dengue; new treatments for psoriasis and atopic dermatitis; clinical manifestations in treatments for new developments in topical therapy; and new developments in medical and pediatric dermatology

Disclosures

  • Bhatt, Mehul D, MD, MBA: no financial relationships exist with commercial interests.
  • Eichenfield, Lawrence F., MD: Allergan, Inc – C(H), I(Fees); Anacor Pharmaceuticals, Inc. – C(H); Cutanea Life Sciences – C(H); Dr. Reddy – C(H); DS Laboratories – C(H); Elsevier Inc. – O(IP); Galderma Laboratories, L.P. – C(H), I(Fees); Genentech, Inc. – C(H); Kimberly Clark – I(Fees); LEO Pharma, US – C(H), I(Fees); Lilly ICOS LLC – C(H); Medimetriks Pharmaceuticals, Inc. – C(H); Novan – C(H), I(Fees); Otsuka Pharmaceutical Co., Ltd. – C(H); Pfizer Inc. – C(H); Ralexar Therapeutics, Inc – C(H); Sanofi/Regeneron – C(H), I(Fees); Tioga Pharmaceuticals, Inc. – C(H); TopMD – C(SO); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Fees); Wiley-Blackwell – O(H);
  • Guttman, Emma, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Allergan, Inc – A(H); Allergan, Inc. – C(H); Almirall – C(H); Amgen – C(H); Asana Biosciences, LLC – A(H), C(H), I(Grants/Research Funding); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Concert Pharmaceuticals – C(H); Dermavant Sciences – A(H), I(Grants/Research Funding); Dermira – A(H), C(H); DS Biopharma – C(H), I(Grants/Research Funding); Eli Lilly and Company – C(H), I(Grants/Research Funding); EMD Serono – C(H); Escalier – C(H); FLX Bio – C(H); Galderma Research & Development, LLC – A(H), C(H); Glenmark Generics Inc. – B(H), C(H), I(Grants/Research Funding); Innovaderm Research Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – C(H); Leo Pharma Inc – A(H), C(H), I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novan – I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), C(H); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron – A(H), C(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); sanofi-aventis – C(H); Sanofi/Regeneron – B(H); Union Therapeutics – C(H);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Avotres, Inc. – C(H); BirchBioMed – C(H); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Cara Therapeutics – C(H); Castle Biosciences, Inc – C(H); Celgene Corporation – I(Grants/Research Funding); Clinuvel – I(Grants/Research Funding); Corrona, Inc. – O(H); Dermavant Sciences – C(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Inozyme Pharma – C(H); Janssen Research & Development, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); LEO Pharma, US – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Meiji Seika Pharma Co., Ltd – C(H); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Rigel, Darrell S., MD: Aclaris Therapeutics, Inc. – C(H); Beiersdorf, Inc. – A(H); Castle Biosciences – A(H), I(Grants/Research Funding); Derm Tech International – A(H), C(H); Ferndale Laboratories, Inc. – C(H); Foamix – SH(SO); LEO Pharma, US – A(H); Myriad Genetics Inc – A(H); Novartis – A(H); Ortho Dermatologics – A(H); Pierre Fabre Dermo-Cosmétique US – A(H); SciBASE – C(H);
  • Stein Gold, Linda F., MD: AbbVie – A(H); Actavis – SP(H); Allergan, Inc. – I(Grants/Research Funding); Aqua – A(H); Dermavant Sciences – A(H); Dermira – SP(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); La Roche-Posay Laboratorie Pharmaceutique – A(H); Leo Pharma Inc. – I(Grants/Research Funding); LEO Pharma, US – A(H); Lilly ICOS LLC – A(H); Merz Pharmaceuticals, LLC – A(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – A(H), I(Grants/Research Funding); Promius Pharmaceuticals – A(H); Roche Laboratories – Independent Contractor(Fees), O(H); Sol-Gel Technologies – C(Grants/Research Funding); Taro Pharm – A(H), C(H); Topica – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H), I(Grants/Research Funding);
  • Strober, Bruce Elliot, MD, PhD: AbbVie – A(H), C(H), I(NC), O(NC); Affibody – C(Fees); Almirall – C(H); Amgen – C(H), I(NC); Arena Pharmaceuticals – C(Fees); Boehringer Ingelheim – C(H), I(NC); Bristol-Myers Squibb – A(H), C(Fees); Celgene Corporation – A(H), C(H), I(NC); Dermavant Sciences – C(Fees); Dermira – A(H), C(H); Eli Lilly and Company – A(H), C(H), I(NC); Galderma Research & Development, LLC – I(NC); GlaxoSmithKline – C(H); Janssen-Ortho Inc. – A(H), C(H), I(NC), O(NC); Leo Pharma Inc – C(H); Medac Pharma, Inc – C(H); Meiji Seika Pharma Co., Ltd – C(Fees); Menlo Therapeutics – C(H); Merck & Co., Inc – I(NC); Novartis Pharmaceuticals Corp. – A(H), C(H); Ortho Dermatologics – C(H); Pfizer Inc. – A(H), C(H), I(NC); Sanofi/Regeneron – A(H), C(H); Sebela Pharmaceuticals, Inc. – C(Fees); Sirtris Pharmaceuticals, Inc. – C(Fees); Sun Pharmaceutical Industries Ltd. – A(H), C(H), I(NC); UCB – A(H), C(Fees);
  • Tomecki, Kenneth J., MD: no financial relationships exist with commercial interests.
  • Ungar, Jonathan, MD: Janssen Pharmaceuticals, Inc – A(H); Menlo Therapeutics – A(H); UCB – A(H);
Schedule
Saturday, July 27
9:00 AM
Dr. Lebwohl / Introduction
9:04 AM
Dr. Strober / Hot Topics in Psoriasis
9:23 AM
Dr. Guttman / Hot Topics in Atopic Dermatitis
9:42 AM
Dr. Rigel / Hot Topics in Skin Cancer
10:01 AM
Dr. Ungar / Dangerous Dermatoses: TEN, SJS, EM, BP, & PV Pearls
10:20 AM
Dr. Stein Gold / Hot Topics in Topical Therapy
10:39 AM
Dr. Bhatt / Hot Topics in Dermatologic Surgery
10:58 AM
Dr. Eichenfield / Hot Topics in Pediatric Dermatology
11:17 AM
Dr. Tomecki / Hot Topics in Cutaneous Infectious Disease
11:36 AM
Dr. Lebwohl / Hot Topics in Dermatology Practice
Event Details
  • Date
    Saturday, July 27
  • Time
    9:00 AM - 12:00 PM
  • Location
    Grand Ballroom East
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Mark Lebwohl, MD, FAAD
Speakers
  • Bruce Elliot Strober, MD, PhD, FAAD
  • Darrell S. Rigel, MD, FAAD
  • Emma Guttman, MD, PhD, FAAD
  • Jonathan Ungar, MD, FAAD
  • Kenneth J. Tomecki, MD, FAAD
  • Lawrence F. Eichenfield, MD, FAAD
  • Linda F. Stein Gold, MD, FAAD
  • Mehul D Bhatt, MD, MBA, FAAD